Business Context and Reporting Period
This Form 8-K was filed by Signal Genetics, Inc. (not Viridian Therapeutics, Inc.) on November 29, 2016. The report details the entry into a Material Definitive Agreement regarding the sale of specific intellectual property assets.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data relates to the transaction consideration:
- Base Consideration: $825,000 to be paid by Quest Diagnostics Investments LLC.
- Contingent Consideration: An additional $100,000 if Quest exercises an option to require Signal to operate its lab beyond December 31, 2016 (but not later than January 14, 2017).
- Indemnification Cap: Signal's aggregate liability for indemnification is limited to $825,000, with $206,250 allocated for breaches of certain representations and warranties.
- Indemnification Threshold: A "nuisance provision" requires claims to exceed $41,250 before indemnification obligations are triggered.
Material Changes and Transaction Details
Signal Genetics entered into an Intellectual Property Purchase Agreement to sell all intellectual property assets relating to the MyPRS test ("MyPRS Assets") to Quest Diagnostics Investments LLC. Key terms include:
- Asset Transfer: Signal will assign rights to the UAMS License Agreement and provide necessary IT, software, and firmware.
- Conditions to Closing: The transaction requires Signal stockholder approval and is contingent on the absence of court orders prohibiting the sale. It is also linked to a previously announced Merger Agreement with Miragen Therapeutics, Inc.
- Exclusivity: Until closing, Signal is prohibited from soliciting other offers for the MyPRS Assets.
- Termination Rights: The agreement may be terminated by mutual consent, material breach, failure to close by April 30, 2017, termination of the Merger Agreement, or legal prohibitions.
Outlook, Risks, and Contingencies
Management indicates the closing is anticipated to occur promptly after stockholder approval and satisfaction of other conditions. The closing of the proposed merger with Miragen Therapeutics is expected to occur simultaneously with this transaction.
Risks and Contingencies:
- Stockholder Approval: The transaction is not final until approved by Signal stockholders.
- Merger Dependency: The sale is contingent on the status of the Merger Agreement with Miragen Therapeutics.
- Continuing Liability: Signal retains potential liability for indemnification regarding breaches of representations and warranties post-closing.
- Regulatory Risk: The transaction could be blocked by court orders or governmental authorities.
Investor Verification Checklist
- Verify the outcome of the required stockholder vote for both the IP sale and the Miragen Therapeutics merger.
- Confirm whether the Merger Agreement with Miragen Therapeutics remains active or has been terminated.
- Review the upcoming Form S-4 proxy statement/prospectus for detailed financial and operational impacts.
- Assess the potential impact of the $825,000 cash inflow on the company's liquidity given the sale of a core asset (MyPRS).
- Monitor for any legal proceedings or injunctions that could prevent the closing by the April 30, 2017 deadline.